MicroBiopharm

MicroBiopharm Co., Ltd. is a prominent Japanese biotechnology company specializing in the development and manufacture of active pharmaceutical ingredients (APIs) through advanced microbial fermentation and chemical synthesis. Originally the pharmaceutical division of Mercian Corporation, the company has built a global reputation for its expertise in high-potency APIs (HPAPIs), particularly in the fields of immunosuppressants and oncology. As a specialized Contract Development and Manufacturing Organization (CDMO), MicroBiopharm offers a full suite of services including strain improvement, process development, and commercial-scale production. The company utilizes proprietary microbial transformation technologies to produce complex molecules that are difficult to synthesize through conventional chemistry. Since its acquisition by Mitsui & Co. in 2011, MicroBiopharm has expanded its international footprint, serving major pharmaceutical clients worldwide with GMP-compliant manufacturing.